Article Text

Download PDFPDF
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A “Real Life Experience”
  1. Anna Fagotti, MD, PhD*,,
  2. Carmine Conte, MD*,,
  3. Francesca Stollagli, MD*,,
  4. Valerio Gallotta, MD*,
  5. Vanda Salutari, MD*,
  6. Carolina Bottoni, MD*,
  7. Matteo Bruno, MD*,,
  8. Gian Franco Zannoni, PhD, and
  9. Giovanni Scambia, MD, PhD*,
  1. *Gynecologic Oncology, Fondazione Policlinico A. Gemelli, IRCCS;
  2. Università Cattolica del Sacro Cuore; and
  3. Department of Histopathology, Gynecopathology Division, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
  1. Address correspondence and reprint requests to Anna Fagotti, MD, PhD, Gynecologic Oncology, Department of Woman and Child Health, Fondazione Policlinico A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy. E-mail: annafagotti{at}libero.it.

Abstract

Background Platinum-based chemotherapy plus bevacizumab is the new standard of care in stage IVB cervical cancer (CC) patients. In this new scenario, radical surgery could be offered in selected cases with an optimal clinical response. Potential surgical complications related to previous bevacizumab treatment have never been described before in this type of setting.

Methods This is a single-institutional retrospective study on women with CC who received radical pelvic surgery after platinum-based chemotherapy (platinum-taxol) plus bevacizumab.

Results Between April 2016 and September 2017, 15 patients with CC underwent radical surgery after bevacizumab-containing chemotherapy (platinum-taxol) at the Division of Gynecologic Oncology, Catholic University of the Sacred Heart in Rome, Italy.

All patients received at least 3 cycles of treatment. Fourteen (93.4%) patients underwent radical hysterectomy, whereas 1 patient received pelvic anterior exenteration. Median operating time was 290 minutes (range, 220–400), and estimated blood loss was 250 mL (range, 50–1500). Median time of hospitalization was 5 days (range, 2–21). Pathological response in the cervix was complete in 3 cases and microscopic in 1 patient (26.7%). Intraoperative complications occurred in 3 cases: 2 vascular injuries and 1 ureteral injury. Three patients (20.0% of the whole series) experienced grade 3 complications.

At last follow-up (median time, 9 months), the median overall survival is 13 months (range, 6–31): 7 (46.7%) women were free of disease, 8 (53.3%) patients progressed, and 3 of them died of disease.

Conclusions Radical surgery can be performed in women with CC previously treated with a bevacizumab-containing regimen.

  • Advanced cervical cancer
  • Bevacizumab
  • Radical hysterectomy
  • Surgical complications
  • Chemotherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.